Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.

| Name |
|---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in...
Benzinga Rankings give you vital metrics on any stock – anytime.
You can purchase shares of Taysha Gene Therapies (NASDAQ:TSHA) through any online brokerage.
Other companies in Taysha Gene Therapies’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Taysha Gene Therapies has a consensus price target of $11.13.
The stock price for Taysha Gene Therapies (NASDAQ: TSHA) is $4.79 last updated October 1, 2026 at 5:11 PM EDT.
There are no upcoming dividends for Taysha Gene Therapies.
Taysha Gene Therapies does not have any upcoming earnings scheduled.
There is no upcoming split for Taysha Gene Therapies.
Taysha Gene Therapies is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.